Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Crinone

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
OBJECTIVE To compare outcomes after intramuscular progesterone (IMP) or 8% Crinone vaginal gel for luteal support for day 3… Expand
2008
Highly Cited
2007
Highly Cited
2007
OBJECTIVE To compare the efficacy and tolerability of two different types of vaginal progesterone (P), Crinone 8% gel (Fleet… Expand
  • table 1
  • table 2
  • figure 1
Highly Cited
2005
Highly Cited
2005
OBJECTIVE To demonstrate the comparative efficacy and tolerability of capsules containing 200 mg of P (Utrogest 200) or Crinone 8… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Highly Cited
2002
Highly Cited
2002
The Crinone 8% preparation makes it possible to administer natural progesterone (90 mg) vaginally once daily for luteal phase… Expand
Highly Cited
2001
Highly Cited
2001
OBJECTIVE To compare the efficacy of Crinone 8% intravaginal progesterone gel vs. IM progesterone for luteal phase and early… Expand
Highly Cited
2000
Highly Cited
2000
OBJECTIVE Compare the pharmacokinetics of vaginal progesterone gel (Crinone 8%, 90 mg) with that of oral progesterone (Prometrium… Expand
  • table 1
Highly Cited
1999
Highly Cited
1999
OBJECTIVE To investigate the efficacy and safety of intravaginal Crinone 8% (Columbia Research Laboratories, Miami. FL) versus IM… Expand
1999
1999
OBJECTIVE To evaluate the outcome of IVF-ET after the use of Crinone 8% (Wyeth-Ayerst Laboratories, Inc., Philadelphia, PA… Expand
Highly Cited
1996
Highly Cited
1996
Two progesterone presentations, a vaginal application of 90 mg progesterone per day (Crinone) or 300 mg progesterone administered… Expand